Chengfang Xu

689 citations
37 papers · 514 indexed · h-index 15
Topics
Liver Disease Diagnosis and Treatment (7 papers)Air Quality and Health Impacts (3 papers)PI3K/AKT/mTOR signaling in cancer (3 papers)
Partner nations
ChinaAustraliaMacao

In The Last Decade

Chengfang Xu

33 papers receiving 502 citations

Peers

Chengfang Xu
Comparison fields: 5 of 109
  • Molecular Biology 144
  • Health, Toxicology and Mutagenesis 125
  • Epidemiology 75
  • Cancer Research 65
  • Obstetrics and Gynecology 52
Replace Guoying Zheng with:
Guoying Zheng China
Kun Du China
Ying Chang China
Roland Schindl Germany
Yanni Xiao China
Yongyi Wang China
Xu Yang China
Yumei Wu China
Chengfang Xu relative to Guoying Zheng China Guoying Zheng's profile →
Citations per field
00.5×3.1×
Guoying Zheng · 1×
Citations per year

Countries citing papers authored by Chengfang Xu

Since Specialization
Citations

This map shows the geographic impact of Chengfang Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengfang Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengfang Xu more than expected).

Fields of papers citing papers by Chengfang Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengfang Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengfang Xu. The network helps show where Chengfang Xu may publish in the future.

Co-authorship network of co-authors of Chengfang Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Chengfang Xu. A scholar is included among the top collaborators of Chengfang Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengfang Xu. Chengfang Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 3
3 5
4 0
5 1
6 1
7 3
8 50
9 16
10 84
11 26
12 9
13 31
14 2
15 7
16 21
17
Effect of Different PTEN Status on PI3K/AKT Pathway of Endometrial Cancer Cell Lines
1
18 12
19 15
20 20

About Chengfang Xu

Chengfang Xu is a scholar working on Obstetrics and Gynecology, Hepatology and Health, Toxicology and Mutagenesis, having authored 37 papers that have together received 514 indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (7 papers), Air Quality and Health Impacts (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). The work is most often cited by research in Health, Toxicology and Mutagenesis (125 citations), Obstetrics and Gynecology (52 citations) and Hepatology (43 citations). Chengfang Xu has collaborated with scholars based in China, Australia and Macao. Frequent co-authors include Xin Wang, Wenyu Wu, Fangjun Wang, Xiaomao Li, Yongfeng Qi, Jiang Wu, Yu Sun, Run Wang, Tao Jia and Jia Xiao. Their work appears in journals such as Nature Communications, The Science of The Total Environment and Journal of Hazardous Materials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026